RARA CRAFT DATABASE for FDA Medical Devices
510(k)K243818

FDA DEVICE FACTS

Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate (Blue)

Hartalega NGC Sdn. Bhd.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJanuary 8, 2025PRODUCT CODELZA

Indications for use

Nitrile Powder Free Examination Glove Tested for Use with Chemotherapy Drugs and Fentanyl Citrate (Blue) is a non-sterile disposable device intended for medical purpose that is worn on the examiner’s hand to prevent contamination between patient and examiner. It is also tested to be used against Chemotherapy Drugs and Fentanyl Citrate. The gloves were tested for use with chemotherapy drugs and fentanyl citrate as per ASTM D6978-05 (Reapproved 2019) Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs. Chemotherapy Drug and Concentration Minimum Breakthrough Detection Time in Minutes Carmustine (3.3 mg/ml) 10.2 Cisplatin (1.0 mg/ml) > 240 Cyclophosphamide (20.0 mg/ml) > 240 Dacarbazine (10.0 mg/ml) > 240 Doxorubicin Hydrochloride (2.0 mg/ml) > 240 Etoposide (20.0 mg/ml) > 240 Fluorouracil (50.0 mg/ml) > 240 Methotrexate (25.0 mg/ml) > 240 Mitomycin C (0.5 mg/ml) > 240 Paclitaxel (6.0 mg/ml) > 240 Thiotepa (10.0 mg/ml) 30.2 Vincristine Sulfate (1.0 mg/ml) > 240 Bleomycin Sulfate, 15.0 mg/ml > 240 Bortezomib, 1.0 mg/ml > 240 Busulfan, 6.0 mg/ml > 240 Carboplatin, 10.0 mg/ml > 240 Chloroquine, 50.0 mg/ml > 240 Cyclosporin A, 100.0 mg/ml > 240 Cytarabine, 100.0 mg/ml > 240 Daunorubicin, 5.0 mg/ml > 240 Docetaxel, 10.0 mg/ml > 240 Epirubicin, 2.0 mg/ml > 240 Fludarabine, 25.0 mg/ml > 240 Gemcitabine, 38.0 mg/ml > 240 Idarubicin, 1.0 mg/ml > 240 Ifosfamide, 50.0 mg/ml > 240 Irinotecan, 20.0 mg/ml > 240 Mechlorethamine HCI, 1.0 mg/ml > 240 Melphalan, 5.0 mg/ml > 240 Mitoxantrone, 2.0 mg/ml > 240 Oxaliplatin, 2.0 mg/ml > 240 Paraplatin, 10.0 mg/ml > 240 Retrovir, 10.0 mg/ml > 240 Rituximab, 10.0 mg/ml > 240 Topotecan, 1.0 mg/ml > 240 Trisenox, 1.0 mg/ml > 240 Caution: Testing showed a minimum breakthrough time of 10.2 minutes with Carmustine and 30.2 minutes with Thiotepa. Warning: Do not use with Carmustine and Thiotepa Fentanyl Citrate and Concentration Minimum Breakthrough Detection Time in Minutes Fentanyl Citrate Injection, 100 mcg/2ml > 240

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 1, 2026